TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Operating Income (Loss) USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2024.
  • Teva Pharmaceutical Industries Ltd Operating Income (Loss) for the quarter ending March 31, 2024 was -$218 M, a 1577% decline year-over-year.
  • Teva Pharmaceutical Industries Ltd Operating Income (Loss) for the twelve months ending March 31, 2024 was $228 M.
  • Teva Pharmaceutical Industries Ltd annual Operating Income (Loss) for 2023 was $433 M.
  • Teva Pharmaceutical Industries Ltd annual Operating Income (Loss) for 2022 was -$2.2 B, a 228% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Operating Income (Loss) for 2021 was $1.72 B.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $228 M -$218 M -$205 M -1577% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $433 M $756 M +$1.7 B Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 -$1.26 B $344 M -$80 M -18.9% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-12
Q2 2023 -$1.18 B -$654 M +$313 M +32.4% Apr 1, 2023 Jun 30, 2023 10-K 2024-02-12
Q1 2023 -$1.5 B -$13 M +$700 M +98.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$2.2 B -$940 M -$1.02 B -1321% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$1.18 B $424 M -$199 M -31.9% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-12
Q2 2022 -$980 M -$967 M -$1.55 B -266% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-12
Q1 2022 $569 M -$713 M -$1.15 B -264% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $1.72 B $77 M -$329 M -81% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $2.05 B $623 M +$4.97 B Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$2.92 B $582 M +$409 M +236% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$3.33 B $434 M +$243 M +127% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$3.57 B $406 M +$258 M +174% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 -$3.83 B -$4.34 B -$4.26 B -5260% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $431 M $173 M +$817 M Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$386 M $191 M +$57 M +42.5% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$443 M $148 M +$3.31 B Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 -$3.76 B -$81 M -$97 M -606% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$3.66 B -$644 M -$630 M -4500% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 -$3.03 B $134 M -$1.39 B -91.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$1.64 B -$3.16 B +$9.85 B +75.7% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 -$11.5 B $16 M -$362 M -95.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 -$11.1 B -$14 M +$5.73 B +99.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$16.9 B $1.53 B +$630 M +70.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 -$17.5 B -$13 B -$12.9 B -9401% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 -$4.6 B $378 M -$387 M -50.6% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 -$4.22 B -$5.74 B -$6.1 B -1690% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $1.88 B $895 M -$270 M -23.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 $2.15 B -$137 M -$1.07 B -115% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $3.22 B $765 M -$245 M -24.3% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $3.47 B $361 M -$301 M -45.5% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $3.77 B $1.17 B +$416 M +55.5% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $3.35 B $931 M -$11 M -1.17% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $3.36 B $1.01 B -$102 M -9.17% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $3.47 B $662 M -$263 M -28.4% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $3.73 B $749 M -$223 M -22.9% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $3.95 B $942 M +$382 M +68.2% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $3.57 B $1.11 B +$311 M +38.8% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $3.26 B $925 M +$1.51 B Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $1.75 B $972 M +$98 M +11.2% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 $1.65 B $560 M +$230 M +69.7% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 $1.42 B $801 M +$861 M Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 $558 M -$586 M -$1.59 B -158% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 $2.15 B $874 M -$54 M -5.82% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 $2.21 B $330 M -$280 M -45.9% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 $2.49 B -$60 M -$1.1 B -106% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $3.58 B $1.01 B +$410 M +68.7% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $3.17 B $928 M +$61 M +7.04% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $3.11 B $610 M -$164 M -21.2% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $3.27 B $1.04 B -$153 M -12.9% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $3.43 B $597 M -$478 M -44.5% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $3.9 B $867 M +$33 M +3.96% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $3.87 B $774 M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $1.19 B Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $1.08 B Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $834 M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.